Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 8:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: NRAS Gene Mutation Clear all
Suspended Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumors
Interventions
JSI-1187, Dabrafenib
Drug
Lead sponsor
JS InnoPharm, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced May 21, 2026, 8:07 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma, Ras (Kras or Nras) Gene Mutation, BRAF Gene Mutation, CRAF Gene Mutation, Non-Small Cell Lung Carcinoma, Thyroid Carcinoma, Gliomas, Malignant
Interventions
IK-595
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
15
States / cities
Duarte, California • Orange, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced May 21, 2026, 8:07 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumor, B-Raf Mutation-Related Tumors
Interventions
BGB-3245
Drug
Lead sponsor
MapKure, LLC
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Beverly Hills, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced May 21, 2026, 8:07 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
Interventions
S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Gilbert, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 21, 2026, 8:07 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC
Interventions
RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, RMC-9805
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
26
States / cities
Gilbert, Arizona • Duarte, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced May 21, 2026, 8:07 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Interventions
KIN-2787, KIN-2787 and binimetinib
Drug
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
17
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced May 21, 2026, 8:07 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumors (Phase 1), RAS Mutation
Interventions
AN9025 oral capsule
Drug
Lead sponsor
Adlai Nortye Biopharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Orlando, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced May 21, 2026, 8:07 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
RMC-6236, Gemcitabine, nab-paclitaxel, Irinotecan, Liposomal irinotecan, 5-fluorouracil, leucovorin, Oxaliplatin
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced May 21, 2026, 8:07 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Metastatic or Unresectable Cutaneous Melanoma
Interventions
MEK162, Dacarbazine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
77
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Altamonte Springs, Florida + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2021 · Synced May 21, 2026, 8:07 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
daraxonrasib, docetaxel
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
34
States / cities
Birmingham, Alabama • Long Beach, California • New Haven, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced May 21, 2026, 8:07 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
ERAS-007, Encorafenib, Cetuximab, Palbociclib
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Duarte, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced May 21, 2026, 8:07 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
Interventions
ompenaclid, FOLFIRI, Bevacizumab, FOLFOX regimen
Drug
Lead sponsor
Inspirna, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
17
States / cities
Prescott Valley, Arizona • Tucson, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced May 21, 2026, 8:07 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation, Melanoma, NSCLC, Glioma, Solid Tumor, Adult, MAPK Pathway Gene Mutation
Interventions
NST-628
Drug
Lead sponsor
Nested Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
17
States / cities
San Francisco, California • Westwood, Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 21, 2026, 8:07 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
RAS Mutation, NRAS Gene Mutation, Melanoma
Interventions
OKI-179 + binimetinib
Drug
Lead sponsor
OnKure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Phoenix, Arizona • San Francisco, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced May 21, 2026, 8:07 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Colorectal Cancer
Interventions
Onvansertib, FOLFIRI, Bevacizumab
Drug
Lead sponsor
Cardiff Oncology
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
27
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced May 21, 2026, 8:07 PM EDT
Available No phase listed Expanded access
View directory record Official record
Conditions
Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma, Non Small Cell Lung Cancer, Thyroid Cancer, Bladder Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer, Cholangiocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, MAPK Gene Mutation, KRAS Activating Mutation, BRAF Gene Mutation, NRAS Gene Mutation, HRAS Gene Mutation, MEK Mutation, ERK Mutation
Interventions
Ulixertinib (BVD-523)
Drug
Lead sponsor
xCures
Industry
Eligibility
12 Years and older
U.S. locations
27
States / cities
Huntsville, Alabama • Mobile, Alabama • Arroyo Grande, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced May 21, 2026, 8:07 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Navitoclax, Positron Emission Tomography, Trametinib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 21, 2026, 8:07 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
Interventions
Onvansertib, FOLFIRI, Bevacizumab, FOLFOX
Drug
Lead sponsor
Cardiff Oncology
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
41
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced May 21, 2026, 8:07 PM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, NRAS Gene Mutation Negative, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Cetuximab, Irinotecan, Panitumumab, Regorafenib
Biological · Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced May 21, 2026, 8:07 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
NRAS Mutation, NRAS-mutant Advanced Melanoma, NRAS-mutant Solid Tumors, NRAS Q61R, NRAS Q61K, NRAS Q61L, NRAS Q61H, NRAS G12D, NRAS G13R, NRAS G13D, NRAS G12V
Interventions
RLY-8161
Drug
Lead sponsor
Relay Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Boston, Massachusetts • Grand Rapids, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 8:07 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma
Interventions
daraxonrasib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Hartford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 8:07 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC, Colorectal Cancer (CRC), CRC
Interventions
Daraxonrasib, Elironrasib, Zoldonrasib, Ivonescimab, Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only), cetuximab (Cohort C2 Only), Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only), Daraxonrasib (Cohort B1 only)
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Norwich, Connecticut • Nashville, Tennessee • Irving, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 8:07 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
Interventions
daraxonrasib, gemcitabine, nab-paclitaxel
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts • Henderson, Nevada • Maumee, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 8:07 PM EDT